CU20190078A7 - Péptidos útiles en el tratamiento de diabetes - Google Patents

Péptidos útiles en el tratamiento de diabetes

Info

Publication number
CU20190078A7
CU20190078A7 CU2019000078A CU20190078A CU20190078A7 CU 20190078 A7 CU20190078 A7 CU 20190078A7 CU 2019000078 A CU2019000078 A CU 2019000078A CU 20190078 A CU20190078 A CU 20190078A CU 20190078 A7 CU20190078 A7 CU 20190078A7
Authority
CU
Cuba
Prior art keywords
diabetes
treatment
useful peptides
peptides
useful
Prior art date
Application number
CU2019000078A
Other languages
English (en)
Other versions
CU24596B1 (es
Inventor
Vincent Carlier
Jean-Marie Saint-Remy
Elst Luc Vander
Original Assignee
Imcyse Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imcyse Sa filed Critical Imcyse Sa
Publication of CU20190078A7 publication Critical patent/CU20190078A7/es
Publication of CU24596B1 publication Critical patent/CU24596B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)

Abstract

<p>La invención se refiere a péptidos tales como HCPYCSLQPLALEGSLQKRG, útiles en el tratamiento de diabetes tipo 1 y a la generación de célula T CD4+ citolítica.</p>
CU2019000078A 2017-03-09 2018-03-06 Péptidos obtenidos a partir de insulina útiles en el tratamiento de diabetes CU24596B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17160085 2017-03-09
PCT/EP2018/055501 WO2018162498A1 (en) 2017-03-09 2018-03-06 Peptides and methods for the treatment of diabetes

Publications (2)

Publication Number Publication Date
CU20190078A7 true CU20190078A7 (es) 2020-04-02
CU24596B1 CU24596B1 (es) 2022-05-11

Family

ID=58266442

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2019000078A CU24596B1 (es) 2017-03-09 2018-03-06 Péptidos obtenidos a partir de insulina útiles en el tratamiento de diabetes

Country Status (20)

Country Link
US (4) US10808016B2 (es)
EP (1) EP3592765A1 (es)
JP (2) JP7102430B2 (es)
KR (1) KR20190126798A (es)
CN (1) CN110536898B (es)
AU (2) AU2018229741B2 (es)
BR (1) BR112019018616A2 (es)
CO (1) CO2019009080A2 (es)
CU (1) CU24596B1 (es)
IL (1) IL268874B2 (es)
MX (1) MX2019010558A (es)
MY (1) MY192295A (es)
NZ (1) NZ755744A (es)
PE (1) PE20191529A1 (es)
PH (1) PH12019502036A1 (es)
RU (1) RU2761653C2 (es)
SA (1) SA519410007B1 (es)
SG (1) SG11201908275XA (es)
WO (1) WO2018162498A1 (es)
ZA (1) ZA201905851B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2709176T3 (es) 2006-08-11 2019-04-15 Life Sciences Res Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
ES2584430T3 (es) * 2008-02-14 2016-09-27 Life Sciences Research Partners Vzw Estrategias para prevenir y/o tratar las respuestas inmunitarias a los alofactores solubles
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
JP7102430B2 (ja) 2017-03-09 2022-07-19 アンシス・エスア 糖尿病の治療のためのペプチド及び方法
WO2021105371A1 (en) 2019-11-27 2021-06-03 Imcyse Sa Methods for stratifying diabetes patients
US20240189404A1 (en) 2020-05-06 2024-06-13 Imcyse Sa Immunogenic peptides with extended oxidoreductase motifs
EP4146255A1 (en) * 2020-05-06 2023-03-15 Imcyse SA Immunogenic peptides with new oxidoreductase motifs
CA3182369A1 (en) * 2020-05-06 2021-07-22 Imcyse Sa Combination treatment for fumarate-related diseases
JP2024520952A (ja) 2021-06-01 2024-05-27 アンシス・エスア 免疫原性ペプチドを使用した改善された処置方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1945246A4 (en) * 2005-09-22 2009-03-11 Irun R Cohen IMMUNOGENIC FRAGMENTS OF CONSTANT DOMAINS OF THE T CELL RECEPTOR AND PEPTIDES DERIVED THEREFROM
ES2709176T3 (es) 2006-08-11 2019-04-15 Life Sciences Res Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
US9248171B2 (en) 2008-02-14 2016-02-02 Imcyse Sa Immunogenic peptides and their use in transplantation
EP2626081B1 (en) 2008-02-14 2017-03-22 Life Sciences Research Partners VZW Immunogenic control of tumours and tumour cells
ES2584430T3 (es) 2008-02-14 2016-09-27 Life Sciences Research Partners Vzw Estrategias para prevenir y/o tratar las respuestas inmunitarias a los alofactores solubles
ES2637812T3 (es) 2008-02-14 2017-10-17 Life Sciences Research Partners Vzw Inmunoterapia dirigida a patógenos intracelulares
EP2245059B1 (en) * 2008-02-14 2017-09-20 Life Sciences Research Partners VZW Cd4+ t-cells with cytolytic properties
EP2252329B1 (en) 2008-02-14 2015-06-17 Life Sciences Research Partners VZW Elimination of immune responses to viral vectors
EP3156068B1 (en) 2010-03-29 2021-11-03 CNRS (Centre National de la Recherche Scientifique) Pharmaceutical compositions comprising a polypeptide comprising at least one cxxc motif and heterologous antigens and uses thereof
DE11787873T1 (de) 2010-11-25 2013-12-12 Imnate Sarl Immugene Peptide zur Verwendung bei der Vorbeugung und/oder Behandlung von Infektionskrankheiten, Autoimmunerkrankungen, Immunreaktionen auf Allofaktoren, allergischen Erkrankungen, Tumoren, Transplantatabstossungen und Immunreaktionen auf virale Vektoren
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
AU2014343379B2 (en) 2013-11-04 2019-02-14 Uti Limited Partnership Methods and compositions for sustained immunotherapy
GB201418433D0 (en) * 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
CA2995771A1 (en) 2015-09-25 2017-03-30 Imcyse Sa Improved methods and compounds for eliminating immune responses to therapeutic agents
BR112018071466A2 (pt) 2016-04-19 2019-03-19 Imcyse Sa novos peptídeos de ligação a cd1d imunogênicos
JP7102430B2 (ja) 2017-03-09 2022-07-19 アンシス・エスア 糖尿病の治療のためのペプチド及び方法
US20210401976A1 (en) * 2018-11-12 2021-12-30 Imcyse Sa Immunogenic peptides with improved oxidoreductase motifs
CN113906046A (zh) 2019-05-16 2022-01-07 易姆赛斯股份公司 具有包含经修饰半胱氨酸的氧化还原酶基序的免疫原性肽
TWM593454U (zh) 2019-11-11 2020-04-11 競泰股份有限公司 多鑰匙鎖心
WO2021105371A1 (en) 2019-11-27 2021-06-03 Imcyse Sa Methods for stratifying diabetes patients
CA3182369A1 (en) 2020-05-06 2021-07-22 Imcyse Sa Combination treatment for fumarate-related diseases
US20240189404A1 (en) 2020-05-06 2024-06-13 Imcyse Sa Immunogenic peptides with extended oxidoreductase motifs
EP4146255A1 (en) 2020-05-06 2023-03-15 Imcyse SA Immunogenic peptides with new oxidoreductase motifs
AR122023A1 (es) 2020-05-06 2022-08-03 Imcyse Sa Péptidos y métodos para el tratamiento de esclerosis múltiple
JP2024520952A (ja) 2021-06-01 2024-05-27 アンシス・エスア 免疫原性ペプチドを使用した改善された処置方法
AR126654A1 (es) 2021-06-29 2023-11-01 Imcyse Sa Péptidos y métodos para el tratamiento de neuromielitis óptica

Also Published As

Publication number Publication date
KR20190126798A (ko) 2019-11-12
US11760782B2 (en) 2023-09-19
SG11201908275XA (en) 2019-10-30
US20190352348A1 (en) 2019-11-21
IL268874B1 (en) 2023-05-01
IL268874A (en) 2019-10-31
AU2018229741B2 (en) 2021-09-02
US10808016B2 (en) 2020-10-20
RU2761653C2 (ru) 2021-12-13
CU24596B1 (es) 2022-05-11
ZA201905851B (en) 2021-04-28
EP3592765A1 (en) 2020-01-15
IL268874B2 (en) 2023-09-01
JP2022125216A (ja) 2022-08-26
US11407795B2 (en) 2022-08-09
PH12019502036A1 (en) 2020-06-15
US12583891B2 (en) 2026-03-24
MY192295A (en) 2022-08-17
AU2021277735A1 (en) 2021-12-23
CN110536898A (zh) 2019-12-03
CO2019009080A2 (es) 2019-08-30
PE20191529A1 (es) 2019-10-23
RU2019126232A (ru) 2021-04-10
NZ755744A (en) 2023-07-28
RU2019126232A3 (es) 2021-06-01
MX2019010558A (es) 2019-10-21
US20240092843A1 (en) 2024-03-21
WO2018162498A1 (en) 2018-09-13
AU2018229741A1 (en) 2019-08-15
US20200407406A1 (en) 2020-12-31
JP7102430B2 (ja) 2022-07-19
CN110536898B (zh) 2023-09-08
JP2020509067A (ja) 2020-03-26
BR112019018616A2 (pt) 2020-04-28
SA519410007B1 (ar) 2023-02-16
US20220411476A1 (en) 2022-12-29
CA3051518A1 (en) 2018-09-13

Similar Documents

Publication Publication Date Title
CU20190078A7 (es) Péptidos útiles en el tratamiento de diabetes
MX2020010014A (es) Celulas asesinas naturales y lineas de celulas asesinas naturales modificadas con aumento de la citotoxicidad.
EA201592103A2 (ru) Способы и композиции для усиления cd4+ регуляторных t-клеток
MX2016007063A (es) Peptidos terapeuticos.
TW201614072A (en) CAR-T lymphocytes engineered to home to lymph node B cell zone, skin, or gastrointestinal tract
NI201300143A (es) Coagonista del receptor de glucagón/glp-1
MA38860B1 (fr) Cellule progénitrice immuno-modulatrice (imp)
EP4620521A3 (en) Methods and compositions relating to chondrisomes from cultured cells
PE20160179A1 (es) Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metoxi)benzaldehido
DOP2016000042A (es) Anticuerpos contra el inhibidor del activador de plasminógeno tipo 1 (pai-1) y usos de los mismos
PH12017502255B1 (en) Nrf2 regulators
MY193650A (en) Extracellular matrix compositions
BR112017010177A2 (pt) composição para tratamento de tecido
MX2018007352A (es) Moduladores de la actividad del complemento.
MX2018004121A (es) Receptores de antigeno y usos de los mismos.
EA201700136A1 (ru) Полимерная композиция для слоя элемента слоя
EP4275746A3 (en) Extracellular vesicles derived from osteoblastic lineage cells for therapeutic and diagnostic use
EA201890439A1 (ru) ИММУНООНКОЛОГИЧЕСКАЯ МЕЗОДЕРМАЛЬНАЯ КЛЕТКА-ПРЕДШЕСТВЕННИК (ioMP-КЛЕТКА)
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
SV2017005585A (es) Peptidos lipidados resistentes a proteasas
MX2019002319A (es) Composiciones azeotrópicas o similares a azeótropo de 3,3,3-trifluoropropino y agua.
IN2014CH00151A (es)
NZ717192A (en) Anti-inflammatory tripeptides
MX380572B (es) Composiciones azeotrópicas de 1,3,3,3-tetracloroprop-1-eno y fluoruro de hidrógeno.
CL2020001612A1 (es) Mezclas estables al almacenamiento